Ubs Group Ag Ngm Biopharmaceuticals Inc Transaction History

Ubs Group Ag

  • $400 Billion
  • Q2 2024

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024
SELL
$1.17 - $1.92 $1,600 - $2,626
-1,368 Reduced 2.92%
45,436 $72,000
Q4 2023

Feb 09, 2024
BUY
$0.6 - $1.31 $14,774 - $32,257
24,624 Added 111.02%
46,804 $40,000
Q3 2023

Nov 09, 2023
BUY
$1.05 - $3.37 $23,289 - $74,746
22,180 New
22,180 $23,000
Q1 2023

May 12, 2023
SELL
$3.72 - $5.4 $6,826 - $9,909
-1,835 Reduced 38.79%
2,896 $11,000
Q4 2022

Feb 08, 2023
BUY
$3.41 - $12.93 $16,132 - $61,171
4,731 New
4,731 $23,000
Q1 2022

May 16, 2022
SELL
$13.81 - $18.6 $36,914 - $49,717
-2,673 Closed
0 $0
Q4 2021

Feb 14, 2022
BUY
$17.26 - $22.02 $32,207 - $41,089
1,866 Added 231.23%
2,673 $47,000
Q3 2021

Nov 15, 2021
SELL
$20.15 - $26.19 $83,421 - $108,426
-4,140 Reduced 83.69%
807 $17,000
Q2 2021

Aug 13, 2021
SELL
$15.06 - $30.03 $561,030 - $1.12 Million
-37,253 Reduced 88.28%
4,947 $98,000
Q1 2021

May 12, 2021
BUY
$24.99 - $31.93 $597,261 - $763,127
23,900 Added 130.6%
42,200 $1.23 Million
Q4 2020

Feb 11, 2021
BUY
$16.21 - $31.44 $97,260 - $188,640
6,000 Added 48.78%
18,300 $554,000
Q3 2020

Nov 12, 2020
BUY
$15.59 - $19.97 $42,264 - $54,138
2,711 Added 28.27%
12,300 $196,000
Q2 2020

Jul 31, 2020
SELL
$11.97 - $23.47 $11,311 - $22,179
-945 Reduced 8.97%
9,589 $189,000
Q1 2020

May 01, 2020
SELL
$10.0 - $19.51 $161,250 - $314,598
-16,125 Reduced 60.49%
10,534 $130,000
Q4 2019

Feb 14, 2020
BUY
$9.97 - $20.28 $174,893 - $355,751
17,542 Added 192.41%
26,659 $492,000
Q3 2019

Nov 14, 2019
BUY
$13.09 - $18.19 $103,463 - $143,773
7,904 Added 651.61%
9,117 $127,000
Q2 2019

Aug 14, 2019
BUY
$12.56 - $16.6 $15,235 - $20,135
1,213 New
1,213 $18,000

Others Institutions Holding NGM

# of Institutions
5
Shares Held
2.6M
Call Options Held
300
Put Options Held
0
View Full List

About NGM BIOPHARMACEUTICALS INC

NGM Quotes by TradingView
  • Ticker NGM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 80,365,904
  • Description
  • NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trial...
More about NGM
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email